Tissue microarray technology in breast cancer HER2 diagnostics

Kristof Egervari, Zoltan Szollosi, Z. Nemes

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Tissue microarrays (TMAs) as current medical research tools significantly lower the costs of immunohistochemical examinations (IHC) and fluorescence in situ hybridization (FISH) while enabling high levels of standardization and reliability. Taking HER2 testing of breast cancer into consideration, we assessed the routine applicability of TMAs. A hundred and seventy-four consecutive samples of invasive breast cancer cases were selected. TMAs were constructed in order to conduct double HER2 immunohistochemical analysis and FISH abreast using the conventional slide by slide method. Comparing the immunohistochemical data obtained from TMAs with the routinely processed large sections, we found a 94.5%/92.7%, 85.7%/88.9% and 91.2%/90% concordance at immunohistochemically HER2-negative, HER2 2+ and 3+ cases using the CB11/HercepTest, respectively. FISH performed on TMAs helped to determine Herceptin therapy suitability in all cases, and when discordance was found, we controlled FISH on "large sections". Being able to conduct FISH examinations at a reasonable price with or without prior immunohistochemical analysis, departments confronted with a certain frequency of breast cancer cases might extensively use the type of TMAs applied in our study. This is a relieve not only with regard to diagnostic work using microarrays, but this also allows to take new directions in research by shedding light on certain unusual cases.

Original languageEnglish
Pages (from-to)169-177
Number of pages9
JournalPathology Research and Practice
Volume203
Issue number3
DOIs
Publication statusPublished - Mar 28 2007

Fingerprint

Fluorescence In Situ Hybridization
Breast Neoplasms
Technology
Biomedical Research
Costs and Cost Analysis
Research
Therapeutics

Keywords

  • Breast cancer
  • Fish
  • HER2
  • Immunohistochemistry
  • Tissue microarray

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Tissue microarray technology in breast cancer HER2 diagnostics. / Egervari, Kristof; Szollosi, Zoltan; Nemes, Z.

In: Pathology Research and Practice, Vol. 203, No. 3, 28.03.2007, p. 169-177.

Research output: Contribution to journalArticle

Egervari, Kristof ; Szollosi, Zoltan ; Nemes, Z. / Tissue microarray technology in breast cancer HER2 diagnostics. In: Pathology Research and Practice. 2007 ; Vol. 203, No. 3. pp. 169-177.
@article{7b82d95470c64232b20835d910fbf648,
title = "Tissue microarray technology in breast cancer HER2 diagnostics",
abstract = "Tissue microarrays (TMAs) as current medical research tools significantly lower the costs of immunohistochemical examinations (IHC) and fluorescence in situ hybridization (FISH) while enabling high levels of standardization and reliability. Taking HER2 testing of breast cancer into consideration, we assessed the routine applicability of TMAs. A hundred and seventy-four consecutive samples of invasive breast cancer cases were selected. TMAs were constructed in order to conduct double HER2 immunohistochemical analysis and FISH abreast using the conventional slide by slide method. Comparing the immunohistochemical data obtained from TMAs with the routinely processed large sections, we found a 94.5{\%}/92.7{\%}, 85.7{\%}/88.9{\%} and 91.2{\%}/90{\%} concordance at immunohistochemically HER2-negative, HER2 2+ and 3+ cases using the CB11/HercepTest, respectively. FISH performed on TMAs helped to determine Herceptin therapy suitability in all cases, and when discordance was found, we controlled FISH on {"}large sections{"}. Being able to conduct FISH examinations at a reasonable price with or without prior immunohistochemical analysis, departments confronted with a certain frequency of breast cancer cases might extensively use the type of TMAs applied in our study. This is a relieve not only with regard to diagnostic work using microarrays, but this also allows to take new directions in research by shedding light on certain unusual cases.",
keywords = "Breast cancer, Fish, HER2, Immunohistochemistry, Tissue microarray",
author = "Kristof Egervari and Zoltan Szollosi and Z. Nemes",
year = "2007",
month = "3",
day = "28",
doi = "10.1016/j.prp.2006.12.004",
language = "English",
volume = "203",
pages = "169--177",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "3",

}

TY - JOUR

T1 - Tissue microarray technology in breast cancer HER2 diagnostics

AU - Egervari, Kristof

AU - Szollosi, Zoltan

AU - Nemes, Z.

PY - 2007/3/28

Y1 - 2007/3/28

N2 - Tissue microarrays (TMAs) as current medical research tools significantly lower the costs of immunohistochemical examinations (IHC) and fluorescence in situ hybridization (FISH) while enabling high levels of standardization and reliability. Taking HER2 testing of breast cancer into consideration, we assessed the routine applicability of TMAs. A hundred and seventy-four consecutive samples of invasive breast cancer cases were selected. TMAs were constructed in order to conduct double HER2 immunohistochemical analysis and FISH abreast using the conventional slide by slide method. Comparing the immunohistochemical data obtained from TMAs with the routinely processed large sections, we found a 94.5%/92.7%, 85.7%/88.9% and 91.2%/90% concordance at immunohistochemically HER2-negative, HER2 2+ and 3+ cases using the CB11/HercepTest, respectively. FISH performed on TMAs helped to determine Herceptin therapy suitability in all cases, and when discordance was found, we controlled FISH on "large sections". Being able to conduct FISH examinations at a reasonable price with or without prior immunohistochemical analysis, departments confronted with a certain frequency of breast cancer cases might extensively use the type of TMAs applied in our study. This is a relieve not only with regard to diagnostic work using microarrays, but this also allows to take new directions in research by shedding light on certain unusual cases.

AB - Tissue microarrays (TMAs) as current medical research tools significantly lower the costs of immunohistochemical examinations (IHC) and fluorescence in situ hybridization (FISH) while enabling high levels of standardization and reliability. Taking HER2 testing of breast cancer into consideration, we assessed the routine applicability of TMAs. A hundred and seventy-four consecutive samples of invasive breast cancer cases were selected. TMAs were constructed in order to conduct double HER2 immunohistochemical analysis and FISH abreast using the conventional slide by slide method. Comparing the immunohistochemical data obtained from TMAs with the routinely processed large sections, we found a 94.5%/92.7%, 85.7%/88.9% and 91.2%/90% concordance at immunohistochemically HER2-negative, HER2 2+ and 3+ cases using the CB11/HercepTest, respectively. FISH performed on TMAs helped to determine Herceptin therapy suitability in all cases, and when discordance was found, we controlled FISH on "large sections". Being able to conduct FISH examinations at a reasonable price with or without prior immunohistochemical analysis, departments confronted with a certain frequency of breast cancer cases might extensively use the type of TMAs applied in our study. This is a relieve not only with regard to diagnostic work using microarrays, but this also allows to take new directions in research by shedding light on certain unusual cases.

KW - Breast cancer

KW - Fish

KW - HER2

KW - Immunohistochemistry

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=33847266290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847266290&partnerID=8YFLogxK

U2 - 10.1016/j.prp.2006.12.004

DO - 10.1016/j.prp.2006.12.004

M3 - Article

C2 - 17292562

AN - SCOPUS:33847266290

VL - 203

SP - 169

EP - 177

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 3

ER -